Correlations of disability and biologic alterations in Alzheimer brain and test of significance by a therapeutic trial in humans

Journal of Alzheimer's Disease

Volumn 9, Issue 2, 2006, Pages 207-218

  Blass, John P ^a   Gibson, Gary E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DONEPEZIL; DRUG ADDITIVE; GLUCOSE; MALIC ACID; NEUROLEPTIC AGENT; PLACEBO; RESVERATROL; VITAMIN;

AEROBIC METABOLISM; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN MITOCHONDRION; BRAIN REGION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROBIOLOGY; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 33746048749     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2006-9212     Document Type: Article

References (71)

1. D.J. Selkoe, Toward a remembrance of things past: deciphering Alzheimer disease, Harvey Led 99 (2003-2004), 23-45.
2. J.P. Blass, The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome, Ann N Y Acad Sci 924 (2000), 170-183.
3. P.I. Moreira, K. Honda, Q. Liu, M.S. Santos, C.R. Oliveira, G. Aliev, A. Nunomura, X. Zhu, M.A. Smith and G. Perry, Oxidative stress: the old enemy in Alzheimer's disease pathophysiology, Curr Alzheimer Res 2 (2005), 403-408.
4. R.H. Swerdlow and S.M. Khan, A mitochondrial cascade hypothesis for sporadic Alzheimer's disease, Med Hypotheses 63 (2004), 8-20.
5. P.S. Aisen, K.L. Davis, J.D. Berg, K. Schafer, K. Campbell, R.G. Thomas, M.F. Weiner, M.R. Farlow, M. Sano, M. Grundman and L.J. Thal, A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study, Neurology 54 (2000), 588-593.
6. P.S. Aisen, Anti-inflammatory agents in Alzheimer's disease, Curr Neurol Neurosci Rep 2 (2002), 405-409.
7. M.T. Jensen, M.D. Mottin, J.R. Cracchiolo, R.E. Leighty and G.W. Arendash, Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging, Neuroscience 130 (2005), 667-684.
8. S. Sung, Y. Yao, K. Uryu, H. Yang, V.M. Lee, J.Q. Trojanowski and D. Pratico, Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease, FASEB J 18 (2004), 323-325. Epub 2003 Dec 4.
9. G. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette and J.M. Orgogozo, AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology 64 (2005), 1553-1562.
10. R.C. Petersen, R.G. Thomas, M. Grundman, D. Bennett, R. Doody, S. Ferris, D. Galasko, S. Jin, J. Kaye, A. Levey, E. Pfeiffer, M. Sano, C.H. van Dyck and L.J. Thal, Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment, N Engl J Med 352(23) (9 Jun. 2005), 2379-2388. Epub 2005 Apr 13.
11. B. Desgranges, J.E. Baron, V. de la Sauette, M.C. Petit-Taboue, K. Benali, B. Landau, B. Lechevalier and F. Esuache, The neural substrate of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization, Brain 121 (1998), 611-631.
12. W. Samuel, R.D. Terry, R. DeTeresa, N. Butters and E. Masliah, Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia, Arch Neurol 51 (1994), 772-778.
13. B. Szieles, R. Mielke, M. Grand and W.D. Heiss, P-300 in Alzheimer's disease: Relationships to dementia severity and glucose metabolism, J Neurol Sci 130 (1995), 77-81.
14. I. Slansky, K. Herholz, U. Pietrzyk, J. Kessler, M. Grond, R. Mielke and W.-D. Heiss, Cognitive impairment in Alzheimer's disease correlates with ventricular width and atrophy-corrected cortical glucose metabolism, Neuroradiology 37 (1995), 270-277.
15. W.J. Jagust, J.L. Eberling, B.R. Reed, C.A. Mathis and T.F. Budinger, Clinical studies of cerebral blood flow in Alzheimer's disease, Ann N Y Acad Sci 826 (26 Sep. 1997), 254-262.
16. G. Gibson, R. Martins, J. Blass and S. Gandy, Altered oxidation and signal transduction systems in fibroblasts from Alzheimer patients, Life Sci 59 (1996), 477-489.
17. P. Bubber, V. Haroutunian, G. Fisch, J.P. Blass and G.E. Gibson, Mitochondrial abnormalities in Alzheimer brain: mechanistic implications, Ann Neurol 57 (2005), 695-703.
18. D.A. Fell, Metabolic control analysis: a survey of its theoretical and experimental development, Biochem J 286(Pt 2) (1992), 313-330.
19. S. Sorbi, E.D. Bird and J.P. Blass, Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain, Ann Neurol 13 (1983), 72-78.
20. W. Op den Velde and F.C. Stam, Some cerebral proteins and enzyme systems in Alzheimer's presenile and senile dementia, J Am Geriatr Soc 24 (1976), 12-16.
21. R.C. Mohs, The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials, Genes Brain Behav 4 (2005), 129-133.
22. K.A. Nolan, M.M. Lino, A.W. Seligmann and J.P. Blass, Absence of vascular dementia in an autopsy series from a dementia clinic, J Am Geriatr Soc 46 (1998), 597-604.
23. W.F. Yu, A. Nordberg, R. Ravid and Z.Z. Guan, Correlation of oxidative stress and the loss of the nicotinic receptor alpha 4 subunit in the temporal cortex of patients with Alzheimer's disease, Neurosci Lett 338 (2003), 13-16.
24. C.S. Casley, L. Canevari, J.M. Land, J.B. Clark and M.A. Sharpe, Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities, J Neurochem 80 (2002), 91-100.
25. G.W. Small, L.M. Ercoli, D.H. Silverman, S.C. Huang, S. Komo, S.Y. Bookheimer, H. Lavretsky, K. Miller, P. Siddarth, N.L. Rasgon, J.C. Mazziotta, S. Saxena, H.M. Wu, M.S. Mega, J.L. Cummings, A.M. Saunders, M.A. Pericak-Vance, A.D. Roses, J.R. Barrio and M.E. Phelps, Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease, Proc Natl Acad Sci USA 97 (2000), 6037-6042.
26. E.M. Reiman, R.J. Caselli, L.S. Yun, K. Chen, D. Bandy, S. Minoshima, S.N. Thibodeau and D. Osborne, Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E, N Engl J Med 334 (1996), 752-758.
27. T. Nihashi, S. Inao, Y. Kajita, T. Kawai, T. Sugimoto, M. Niwa, R. Kabeya, N. Hata, S. Hayashi and J. Yoshida, Expression and distribution of beta amyloid precursor protein and beta amyloid peptide in reactive astrocytes after transient middle cerebral artery occlusion, Acta Neurochir (Wien) 143 (2001), 287-295.
28. J.P. Blass, A.C. Baker, L. Ko and R.S. Black, Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation, Arch Neurol 47 (1990), 864-869.
29. B. Cheng and M.P. Mattson, Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: prevention by NGF and bFGF, Exp Neurol 117 (1992), 114-123.
30. D. Chu, J. Qiu, M. Grafe, R. Fabian, T.A. Kent, D. Rassin, O. Nesic, K. Werrbach-Perez and R. Perez-Polo, Delayed cell death signaling in traumatized central nervous system: hypoxia, Neurochem Res 27 (2002), 97-106.
31. G.S. Watson and S. Craft, Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease, Eur J Pharmacol 490 (2004), 97-113.
32. E. Steen, B.M. Terry, E.J. Rivera, J.L. Cannon, T.R. Neely, R. Tavares, X.J. Xu, J.R. Wands and S.M. de la Monte, Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7(1) (Feb. 2005), 63-80.
33. C.D. Lynch, D. Lyons, A. Khan, S.A. Bennett and W.E. Sonntag, Insulin-like growth factor-1 selectively increases glucose utilization in brains of aged animals, Endocrinology 142 (2001), 506-509.
34. G.E. Gibson, Interactions of oxidative stress with cellular calcium dynamics and glucose metabolism in Alzheimer's disease, Free Radic Biol Med 32 (2002), 1061-1070.
35. J.P. Blass, R.K. Sheu and G.E. Gibson, Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise, Ann N Y Acad Sci 903 (2000), 204-221.
36. J.A. Luchsinger and R. Mayeux, Dietary factors and Alzheimer's disease, Lancet Neurol 3 (2004), 579-587.
37. J.P. Blass, Effects of free radical quenchers in foods: Chemistry and fantasy, J Neurochem 94(75) (2005), and, in preparation.
38. B. Frank and S. Gupta, A review of antioxidants and Alzheimer's disease, Ann Clin Psychiatry 17 (2005), 269-286.
39. D.Q. Pham and R. Plakogiannis, Vitamin e supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: part 2, Ann Pharmacother 39 (2005), 2065-2071. Epub 2005 Nov 15.
40. B. Rumble, R. Retallack, C. Hilbich, G. Simms, G. Multhaup, R. Martins, A. Hockey, P. Montgomery, K. Beyreuther and C.L. Masters, Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease, New Eng J Med 320 (1989), 1446-1452.
41. W.M. Pardridge, J.L. Buciak, J. Yang, B.L. Miller and H.V. Vinters, Measurement of amyloid peptide precursor of Alzheimer disease in human blood by double antibody immunoradiometric assay, Alzheimer Dis Assoc Disord 5 (1991), 12-24.
42. S. Brettschneider, N.G. Morgenthaler, S.J. Teipel, C. Fischer-Schulz, K. Burger, R. Dodel, Y. Du, H.J. Moller, A. Bergmann and H. Hampel, Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radio labeled amyloid beta(1-42) peptide, Biol Psychiatry 57 (2005), 813-816.
43. E.R. Peskind, J. Leverenz, M.R. Farlow, R.K. Ito, S.A. Provow, R.S. Siegel, M. Cleveland, C.H. Morgan, M.R. Pandian, S. Corbin, D. Nochlin, G.D. Schellenberg, M.A. Raskind and S.L. Wagner, Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls, Alzheimer Dis Assoc Disord 11 (1997), 201-206.
44. C. Pereira, P. Agostinho, P.I. Moreira, S.M. Cardoso and C.R. Oliveira, Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies, Curr Drug Targets CNS Neurol Disord 4(4) (Aug. 2005), 383-403.
45. S. Barghorn, V. Nimmrich, A. Striebinger, C. Krantz, P. Keller, B. Janson, M. Bahr, M. Schmidt, R.S. Bitner, J. Harlan, E. Barlow, U. Ebert and H. Hillen, Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease, J Neurochem 95 (2005), 834-847. Epub 2005 Aug 31.
46. A. Piccini, C. Russo, A. Gliozzi, A. Relini, A. Vitali, R. Borghi, L. Giliberto, A. Armirotti, C. D'Arrigo, A. Bachi, A. Cattaneo, C. Canale, S. Torrassa, T.C. Saido, W. Markesbery, P. Gambetti and M. Tabaton, β-Amyloid is different in normal aging and in Alzheimer disease, J Biol Chem 280 (2005), 34186-34192. Epub 2005 Aug 15.
47. R.D. Terry, L.A. Hansen, R. DeTeresa, P. Davies, H. Tobias and R. Katzman, Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles, J Neuropathol Exp Neurol 46 (1987), 262-268.
48. C. Bancher, K. Jellinger, H. Lassmann, P. Fischer and F. Leblhuber, Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia, Eur Arch Psychiatry Clin Neurosci 246 (1996), 137-146.
49. R.D. Terry, Cell death or synaptic loss in Alzheimer disease, J Neuropathol Exp Neurol 59 (2000), 1118-1119.
50. R.D. Terry, A. Peck, R. DeTeresa, R. Schechter and D.S. Horoupian, Some morphometric aspects of the brain in senile dementia of the Alzheimer type, Ann Neurol 10 (1981), 184-192.
51. K.M. Bradley, G.M. Bydder, M.M. Budge, J.V. Hajnal, S.J. White, B.D. Ripley and A.D. Smith, Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease, Br J Radiol 75 (2002), 506-513.
52. L.A. van de Pol, A. Hensel, F. Barkhof, H.J. Gertz, P. Scheltens and W.M. van der Flier, Hippocampal atrophy in Alzheimer disease: age matters, Neurology 66 (2006), 236-238.
53. C. Zarow, H.V. Vinters, W.G. Ellis, M.W. Weiner, D. Mungas, L. White and H.C. Chui, Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia, Ann Neurol 57 (2005), 896-903.
54. R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, L.A. Hanson and R. Katzman, Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment, Ann Neurol 30 (1991), 572-580.
55. D.W. Dickson, H.A. Crystal, C. Bevona, W. Honer, I. Vincent and P. Davies, Correlations of synaptic and pathological markers with cognition of the elderly, Neurobiol Aging 16 (1995), 285-298; discussion 298-304.
56. D.S. Baskin, J.L. Browning, F.J. Pirozzolo, S. Koporaal, J.A. Baskin and S.H. Appel, Brain choline acetyltransferase and mental function in Alzheimer disease, Arch Neurol 56 (1999), 112-1123.
57. E.J. Mufson, S.Y. Ma, E.J. Cochran, D.A. Bennett, L.A. Beckett, S. Jaffar, H.U. Saragovi and J.H. Kordower, Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease, J Comp Neurol 427 (2000), 19-30.
58. P. Tiraboschi, L.A. Hansen, M. Alford, E. Masliah, L.J. Thal and J. Corey-Bloom, The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease, Neurology (2000), 1278-1285.
59. R.D. Guzy, B. Hoyos, E. Robin, H. Chen, L. Liu, K.D. Mansfield, M.C. Simon, U. Hammerling and P.T. Schumacker, Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing, Cell Metabolism 1 (2005), 401-408.
60. N. Mohamad, A. Gutierrez, M. Nunez, C. Cocca, G. Martin, G. Cricco, V. Medina, E. Rivera and R. Bergoc, Mitochondrial apoptotic pathways, Biocell 29 (2005), 149-161.
61. H.M. Huang, H.L. Chen, H. Xu and G.E. Gibson, Modification of endoplasmic reticulum Ca(2+) stores by select oxidants produces changes reminiscent of those in cells from patients with Alzheimer disease, Free Radic Biol Med 39 (2005), 979-989.
62. G.E. Gibson, M. Shimada and J.P. Blass, Alterations in acetylcholine synthesis and cyclic nucleotides in mild cerebral hypoxia, J Neurochem 31 (1978), 757-760.
63. J.A. Hirsch and G.E. Gibson, Selective alteration of neurotransmitter release by low oxygen in vitro, Neurochem Res 9 (1984), 1039-1049.
64. G.B. Young, Status epilepticus and brain damage: pathology and pathophysiology, Adv Neurol 97 (2006), 217-220.
65. G.E. Gibson, W. Pulsinelli, J.P. Blass and T.E. Duffy, Brain dysfunction in mild to moderate hypoxia, Amer J Med 70 (1981), 1247-1254.
66. J.P. Blass, G.E. Gibson and S. Hoyer, The role of the metabolic lesion in Alzheimer's disease, J Alzheimers Dis 4 (2002), 225-232.
67. J.P. Blass, Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res 66 (2001), 851-856.
68. P. Schonknecht, J. Pantel, T. Hartmann, E. Werle, M. Volkmann, M. Essig, M. Amann, N. Zanabili, H. Bardenheuer, A. Hunt and J. Schroder, Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy, Psychiatry Res 120 (2003), 231-238.
69. T. den Heijer, P.E. Sijens, N.D. Prins, A. Hofman, P.J. Koudstaal, M. Oudkerk and M.M.M.R. Breteler, spectroscopy of brain white matter in the prediction of dementia, Neurology 66(4) (28 Feb. 2006), 540-544.
70. M.N. Sabbagh, P. Lynn, S. Jhingran, P. Massman, J. Villanueva-Meyer, J. Olup and R.S. Doody, Correlations between SPECT regional cerebral blood flow and psychometric testing in patients with Alzheimer's disease, J Neuropsychiatry Clin Neurosci 9 (1997), 68-74.
71. J.P. Blass, Metabolic enhancement for the treatment of Alzheimer disease, Research and Practice in Alzheimer's Disease and Cognitive Decline 9 (2002), 282-287.